Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Mar 3, 2026 · Filed Mar 4, 2026
Quest Diagnostics's SVP & General Counsel sold $109K of Quest Diagnostics shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$109,266
Shares × reported transaction price
21 days after results of Feb 10, 2026, 49 days before results of Apr 21, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $208.36 on Mar 3, 2026, within 2% of its 52-week high, after a 10% rise over the previous 30 trading days
52-week range $159.80 (Apr 8, 2025) to $211.91 (Feb 27, 2026), 93% of the way up, from 251 adjusted closes. 30 trading days earlier: $189.49 on Jan 16, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.5% | -2.2% | +0.7% |
| 30 days | -2.5% | -3.3% | +0.8% |
| 90 days | -5.0% | +10.7% | -15.8% |
| 180 days | +15.8% | +11.8% | +4.0% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
